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It’s About Lyme: Why Congress Must Enact Medical
Insurance Coverage Laws for Lyme Disease Patients
Now
Jennifer Barrett*
“In the fullness of time, the mainstream handling of
chronic Lyme disease will be viewed as one of the most
shameful episodes in the history of medicine because
elements of academic medicine, elements of government
and virtually the entire insurance industry have colluded
to deny a disease.”
—Dr. Kenneth Liegner1
Dr. Neil Spector was a prominent oncologist who began
experiencing heart problems of an unknown origin in 1994 at the age of
thirty-seven.2 He had no recollection of a tick bite or rash, but he suspected
Lyme disease was the cause of his illness because he spent years hiking
and jogging in New England.3 Unfortunately, his first two Centers for
Disease Control and Prevention (CDC) approved blood antibody tests for
Lyme disease came back inconclusive.4 As a result, his doctor diagnosed
him with third-degree heart block of an unknown origin and gave him a
pacemaker.5 Frustrated by the test results, Dr. Spector began researching
*

J.D. Candidate, 2022, Seattle University School of Law; B.S. Civil Engineering and MBA,
University of New Hampshire. I would like to thank Seattle University Law Review and the SUpra
editors for their assistance in the publication process. I would also like to thank Dr. Steven Harris and
Theresa Denham for their guidance and helpful feedback as well as my friends and family for their
support.
1. Letter from Kenneth B. Liegner, Kenneth B. Liegner, M.D., P.C. & Assocs. to Lonnie King,
Trevonne Walford, Christine M. Coussens, Members of the IOM Comm. Panel for “Lyme Disease &
Other Tick-borne Diseases: State of Science,” Inst. of Med. of the Nat’l Acad. of Scis. (Sept. 14, 2010),
in KENNETH B. LIEGNER, IN THE CRUCIBLE OF CHRONIC LYME DISEASE 769–70 (2015).
2. NEIL SPECTOR, GONE IN A HEARTBEAT: A PHYSICIAN’S SEARCH FOR TRUE HEALING 42–44
(2015).
3. Id. at 62.
4. Id. at 73–74. Dr. Spector’s antibodies were abnormal, but he did not meet the CDC standard
for a positive test; thus, his doctor ruled the test a false-positive. Id.
5. Id. at 60.
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Lyme and realized that his symptoms, including heart block, arthritis, and
weight loss, were all symptoms of Lyme disease.6 In his book, Gone in a
Heartbeat, Dr. Spector wrote: “Despite my instincts and research into the
field, I was largely being discounted by the medical community. If this can
happen to a physician-scientist with extensive knowledge of medicine, just
imagine what is happening to others who lack a medical background.”7 In
1997, Dr. Spector’s third Lyme test finally came back positive, but it was
too late for antibiotics therapy—the common treatment for Lyme
disease—to reverse the damage to his heart.8 Dr. Spector required a heart
transplant in 2009 at the age of fifty-three and died in 2020.9
Vicki Logan was a thirty-nine year old pediatric ICU nurse with
unexplained symptoms of gait disturbance and chronic meningitis with no
history of rash or tick bite.10 Her CDC-approved blood antibody test for
Lyme disease came back negative in 1989.11 Suspecting her illness might
be related to Lyme, her doctor treated her with twenty-one days of
intravenous (IV) antibiotics, “thought to be curative for the illness,” and
an additional four months of oral antibiotics, yet she did not get better.12
Without a clear diagnosis, her doctor discontinued treatment.13 A year
later, with her condition worsening, Ms. Logan begged her doctor for
another test.14 Obliging, her doctor sent spinal fluid to the CDC, where
scientists cultured Lyme bacteria from Ms. Logan’s spinal fluid, a first for
an American patient who had received “curative antibiotic treatment.”15
Despite a confirmed diagnosis, Ms. Logan struggled to receive
reimbursement from her private insurance company, which claimed her
treatment was “not medically necessary” and “experimental.”16 While on
IV antibiotics, she experienced improvements, but her condition
deteriorated each time she stopped.17 Ms. Logan died in 2003 at the age of

6. Id. at 77.
7. Id. at 78.
8. Id. at 88, 106–08.
9. Id. at 185. Dr. Spector died in June 2020 at the age of sixty-three. Julie Poucher Harbin, Gone
Too Soon: Dr. Neil Spector Passes Away, DUKE CANCER INST. (June 17, 2020),
http://www.dukecancerinstitute.org/news/gone-too-soon-dr-neil-spector-passes-away
[https://perma.cc/N6CN-ZAPB].
10. Pamela Cocks, The Case of Vicki Logan, LYME TIMES, Spring 2015, at 8, 8; KENNETH B.
LIEGNER, IN THE CRUCIBLE OF CHRONIC LYME DISEASE 789–90 (2015).
11. Cocks, supra note 10; LIEGNER, supra note 10.
12. LIEGNER, supra note 11, at 790.
13. Id.
14. Id.; Cocks, supra note 11.
15. LIEGNER, supra note 11, at 790.
16. Id. at 791–92.
17. Id. at 790–95.
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fifty-three during a pause in treatment awaiting Medicaid
preauthorization.18
Dr. Spector’s and Ms. Logan’s deaths highlight the suffering that
many patients with persistent Lyme disease face due to the complexity of
the disease, the inaccuracy of the current CDC-approved blood antibody
test for Lyme disease, and insurance companies’ denial of coverage. While
scientists hope to find a cure and develop better tests in the coming years,
current Lyme patients cannot wait; they need help now. That is why I urge
Congress to pass a law requiring insurance companies to pay for treatment
and provide valuable tracking information on how many people are
suffering from this disease, as outlined in this Note.
INTRODUCTION
Borrelia burgdorferi (Lyme disease) is a bacterial infection, which
is transmitted primarily through tick bites.19 It was discovered in Lyme,
Connecticut in 1976 after several children fell ill with juvenile arthritis of
an unknown origin.20 Today, the Centers for Disease Control and
Prevention (CDC) estimates that approximately 476,000 Americans fall ill
to Lyme disease each year,21 and patients with Lyme disease reside in all
fifty states.22 Despite the prevalence of Lyme disease, the National
Institute of Health (NIH) spent $40 million on research in 2020 compared
to $275 million on research for Malaria, 23 which averages only 2,000 new
diagnoses per year in the United States.24 Patients who receive early
treatment for Lyme disease typically recover with a short course of
antibiotics, but up to 160,000 new patients each year may experience

18. PAMELA WEINTRAUB, CURE UNKNOWN: INSIDE THE LYME EPIDEMIC 312–13 (rev. ed.
2013).
19. The History of Lyme Disease, IGENEX, https://igenex.com/tick-talk/the-history-of-lymedisease/ [https://perma.cc/8B5Z-YZC5].
20. Id.
21. How Many People Get Lyme Disease?, CTRS. FOR DISEASE CONTROL & PREVENTION (Jan.
13, 2021), https://www.cdc.gov/lyme/stats/humancases.html [https://perma.cc/T4VH-R4CF]
[hereinafter How Many People Get Lyme Disease?].
22. Linda Searing, The Big Number: Lyme Disease is Now in 100 Percent of the U.S., WASH.
POST (Aug. 4, 2018), https://www.washingtonpost.com/national/health-science/the-big-numberlyme-disease-is-now-in-100-percent-of-the-us/2018/08/03/d35768ec-965e-11e8-810c5fa705927d54_story.html [https://perma.cc/MK7D-4QCA].
23. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC),
NAT’L INST. OF HEALTH (June 25, 2021), https://report.nih.gov/funding/categorical-spending/
[https://perma.cc/MA7F-CUMA] [hereinafter NIH Estimates of Funding] (noting that the Malaria
number includes $64 million for the Malaria vaccine).
24. About Malaria, CTRS. FOR DISEASE CONTROL & PREVENTION (Mar. 12, 2020),
https://www.cdc.gov/malaria/about/ [https://perma.cc/TX4B-JANP] [hereinafter About Malaria].
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persistent symptoms, which could last for years.25 Due to the ongoing
medical debate on how to treat persistent Lyme, insurance companies
freely restrict access to treatment, leaving patients to bear much of the
financial burden.26
This Note urges Congress to enact legislation mandating insurance
companies to pay for clinically diagnosed Lyme disease and co-infections
treatment, based on the International Lyme and Associated Diseases
Society’s Guidelines, to reduce the financial burden unfairly placed on
Lyme disease patients. Congress should also enact legislation that requires
insurance companies to report all claims, including treatment denials, to
hold them accountable and provide much needed analytical information
on how many people suffer from this disease. Although some litigants
have attempted to hold insurance companies and medical associations
accountable through antitrust litigation, the process can be slow and may
not address the widespread issue, necessitating federal legislation. Parts I
and II provide an overview of Lyme disease and discuss how the medical
debate about Lyme disease restricts patients’ access to proper medical
care. Parts III and IV discuss legal issues and treatment costs. Parts V and
VI outline Lyme specific state insurance law mandates and the World
Health Organization’s new Lyme disease codes for persistent infection.
Part VII provides proposed federal legislation based on state Lyme
legislation and federal laws for other illnesses.
I. LYME DISEASE OVERVIEW
Lyme disease is caused by spiral shaped bacteria (spirochetes) and is
spread primarily through tick bites,27 although scientists have also
documented cases of mother to fetus transmissions.28 Early Lyme disease
often has flu-like symptoms including headache, fever, migrating arthriticlike joint pain, and Bell’s palsy.29 At this early stage, the disease can
25. Up to 35% of patients develop persistent Lyme (476,000 x 0.35 = 166,600). TICK-BORNE
DISEASE WORKING GROUP, 2020 REPORT TO CONGRESS 62–63 (2020) [hereinafter 2ND REPORT TO
CONGRESS].
26. See, e.g., UNITEDHEALTHCARE OXFORD, UNITEDHEALTHCARE OXFORD CLINICAL POLICY:
LYME DISEASE 1–2 (2020) [hereinafter UNITEDHEALTHCARE OXFORD CLINICAL POLICY]; see also
Clinical Policy Bulletin Number 0215: Lyme Disease and Other Tick-Borne Diseases, AETNA (Mar.
17, 2021), http://www.aetna.com/cpb/medical/data/200_299/0215.html [https://perma.cc/65GPHQAL] [hereinafter Aetna Clinical Policy]; see also WEINTRAUB, supra note18, at 307.
27. Frequently Asked Questions About Lyme Disease, INT’L LYME & ASSOCIATED DISEASES
EDUC. FOUND., https://iladef.org/education/lyme-disease-faq/ [https://perma.cc/6NMU-U5YW].
28. See Lisa A. Waddell, Judy Greig, L. Robbin Lindsay, Alison F. Hinckley & Nicholas H.
Ogden, A Systematic Review on the Impact of Gestational Lyme Disease in Humans on the Fetus and
Newborn, PLOS ONE, Nov. 12, 2018, at 1, 1.
29. See Elizabeth L. Maloney, The Need for Clinical Judgment in the Diagnosis and Treatment
of Lyme Disease, 14 J. AM. PHYSICIANS & SURGEONS 82, 82–83 (2009).
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usually be treated with a short course of antibiotics without
repercussions.30
If left untreated, however, symptoms often worsen and the risk of
treatment failure increases.31 Late stage Lyme disease can result in
neurologic issues including cognitive dysfunction, memory loss, and
headache; fatigue; chest pain; shortness of breath; difficulty sleeping;
lightheadedness; and psychiatric symptoms such as depression, anxiety,
and mood swings.32 In addition, an estimated 50% of patients suffer from
co-infections, such as Babesia or Bartonella, which can exacerbate
symptoms and require additional treatment.33
Practitioners often fail to diagnose Lyme disease due to the disease’s
non-specific symptoms, poor laboratory tests, and painless rashes from
tick bites that often go unnoticed.34 The most accurate way to diagnose
Lyme disease is by identifying the disease’s signature bull’s-eye rash, yet
only about 68% of people with Lyme disease develop a rash,35 and only
14% of patients remembered being bitten in one study.36 If people do not
know they have been bitten by a tick, they likely will not be on the lookout
for a painless rash.
Another way to diagnose Lyme disease is through a CDC-approved
blood antibody test, which uses two-tier antibody testing. However,
scientists found the test has a sensitivity of only 35.2% in patients
presenting with a rash.37 In addition to the flaws typically found in
antibody testing,38 the CDC-approved Lyme disease test is limited by the
following: (1) it looks for antibodies developed from a single European
30. 2ND REPORT TO CONGRESS, supra note 25, at 46.
31. Daniel J. Cameron, Consequences of Treatment Delay in Lyme Disease, 13 J. EVALUATION
CLINICAL PRAC. 470, 471–72 (2007).
32. Maloney, supra note 29, at 83; Lyme Disease Basics for Providers, INT’L LYME &
ASSOCIATED DISEASES SOC’Y, https://www.ilads.org/research-literature/lyme-disease-basics-forproviders/ [https://perma.cc/ET28-RHSE].
33. Co-infections are other diseases transmitted via tick bite along with Lyme disease. About
Lyme Disease Co-Infections, LYMEDISEASE.ORG, https://www.lymedisease.org/lyme-basics/coinfections/about-co-infections/ [https://perma.cc/CJ5P-J47W].
34. Maloney, supra note 29, at 82–83.
35. Id. at 82.
36. Id. at 83.
37. Gary P. Wormser, Martin Schriefer, Maria E. Aguero-Rosenfeld, Andrew Levin, Allen C.
Steere, Robert B. Nadelman, John Nowakowski, Adriana Marques, Barbara J. B. Johnson & J. Stephen
Dumler, Single-Tier Testing with the C6 Peptide ELISA Kit Compared with Two-Tier Testing for Lyme
Disease, 75 DIAGNOSTIC MICROBIOLOGY INFECTIOUS DISEASE 9,9 (2013). The state of Rhode Island
requires doctors to notify patients that a negative test result does not rule out Lyme disease. 5 R.I.
GEN. LAWS § 5-37.5-6 (2014).
38. The problem with testing antibodies, in general, is that they only show the body’s response
to infection, take weeks to develop, and may still exist after infections are gone. Diagnosis and Testing,
CTRS.
FOR
DISEASE
CONTROL
&
PREVENTION
(Nov.
20,
2019),
https://www.cdc.gov/lyme/diagnosistesting/index.html [https://perma.cc/67LE-YVL8].
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strain of the bacteria, without regard to the hundreds of other strains found
in the U.S. and around the world; (2) it is based on antibodies created by
patients with early arthritic symptoms, as opposed to patients with later
neurologic symptoms; and (3) it relies on non-specific antibodies, which
could be attributed to other illnesses, while excluding antibodies more
specific to Lyme disease.39 As a result, 22% of patients with early stage
Lyme disease test negative and roughly half of patients with late-stage,
neurologic Lyme disease also test negative.40
Given the flaws in rash identification and blood tests, doctors must
rely on symptoms to accurately diagnose patients.41 This requires doctors
to evaluate the unique, systemic nature of the illness: “[A] single symptom
means little but four or five may, for all practical purposes, make the
case. . . . [T]he combination of fatigue, [tingling], [joint pain], and
memory complaints presenting in a single patient commands the attention
of physicians.”42 Thus the full body, systemic nature of the illness allows
doctors to accurately diagnose the illness clinically.
II. THE MEDICAL DEBATE
Two medical societies—Infectious Diseases Society of America
(IDSA)43 and International Lyme and Associated Diseases Society
(ILADS)44—currently provide guidelines on Lyme disease treatment
based on expert opinion and scientific research, but their guidance varies
widely, especially on the topic of persistent illness, resulting in drastic and
disparate consequence for patients. Insurance companies presumably
follow the IDSA Guidelines because they require only minimal treatment,
leaving patients who seek additional treatment in-line with ILADS
Guidelines to bear most of the costs of additional treatment out-of39. WEINTRAUB, supra note18, at 10, 320.
40. Maloney, supra note 29, at 82 (discussing the flaws associated with requiring a positive test
to confirm diagnosis).
41. Lorraine Johnson & Raphael B. Stricker, Treatment of Lyme Disease: A Medicolegal
Assessment, 2 EXPERT REV. ANTI-INFECTIVE THERAPY 533, 535 (2004) [hereinafter Medicolegal
Assessment].
42. Maloney, supra note 29, at 84.
43. “The [IDSA] is a community of over 12,000 physicians, scientists and public health experts
who specialize in infectious diseases. Our mission is to improve the health of individuals,
communities, and society by promoting excellence in patient care, education, research, public health,
and prevention relating to infectious diseases.” About IDSA, INFECTIOUS DISEASES SOC’Y AM.,
https://www.idsociety.org/about-idsa/about-idsa/ [https://perma.cc/AA3Q-4PC6].
44. “ILADS is a nonprofit, international, multidisciplinary medical society dedicated to the
appropriate diagnosis and treatment of Lyme and associated diseases. ILADS promotes understanding
of Lyme and associated diseases through research, education[,] and policy. We strongly support
physicians, scientists, researchers and other healthcare professionals dedicated to advancing the
standard of care for Lyme and associated diseases.” Mission & Goals, INT’L LYME & ASSOCIATED
DISEASES SOC’Y, https://www.ilads.org/about/mission/ [https://perma.cc/J4FG-HSR2].
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pocket.45 This is one of several reasons why it is imperative that Congress
enacts legislation that allows patients to seek coverage aligned with either
set of guidelines for patients diagnosed with Lyme disease.
The medical debate on persistent infection hinges on the accuracy of
tests and clinical diagnoses, duration of treatment, and the cause of
persistent symptoms. The IDSA categorizes Lyme as a disease that is
difficult to get and easy to cure.46 Further, the IDSA claims symptoms that
persist after treatment are the result of unexplained, subjective symptoms
it calls post-Lyme disease syndrome (PLDS).47 ILADS, on the other hand,
recognizes Lyme disease as a complex disease that can cause
complications if not caught early or treated effectively.48 ILADS states that
persistent symptoms lasting more than six months are the result of
persistent infection, which it calls “chronic Lyme disease.”49 The term
“chronic Lyme disease” is steeped in controversy because IDSA doctors
believe the diagnosis constitutes medical fraud;50 whereas, ILADS doctors
believe the term accurately describes patients with complex infection
beyond the acute phase.51 Despite the controversy, the term “chronic Lyme
disease” will be used throughout this Note because it is central to the need
for insurance coverage.

45. See 2ND REPORT TO CONGRESS, supra note 25, at 63, 101–02.
46. Gina Kolata, Lyme Disease Is Hard to Catch and Easy to Halt, Study Finds, N.Y. TIMES
(June 13, 2001), https://www.nytimes.com/2001/06/13/us/lyme-disease-is-hard-to-catch-and-easy-tohalt-study-finds.html [https://perma.cc/MS4Q-76NL].
47. Gary P. Wormser, Raymond J. Dattwyler, Eugene D. Shapiro, John J. Halperin, Allen C.
Steere, Mark S. Klempner, Peter J. Krause, Johan S. Bakken, Franc Strle, Gerold Stanek, Linda
Bockenstedt, Durland Fish, J. Stephen Dumler & Robert B. Nadelman, The Clinical Assessment,
Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis:
Clinical Practice Guidelines by the Infectious Diseases Society of America, 43 CLINICAL INFECTIOUS
DISEASES 1089, 1120–21 (2006) [hereinafter 2006 IDSA Guidelines]. PLDS is synonymous with
PTLDS (Post-Treatment Lyme Disease Syndrome).
48. See Daniel J. Cameron, Lorraine B. Johnson & Elizabeth L. Maloney, Evidence Assessments
and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites,
Erythema Migrans Rashes and Persistent Disease, EXPERT REV. ANTI-INFECTIVE THERAPY 1103,
1104 (2014) [hereinafter 2014 ILADS Guidelines].
49. Samuel Shor, Christine Green, Beatrice Szantyr, Steven Phillips, Kenneth Liegner, Joseph
Burrascano Jr., Robert Bransfield & Elizabeth L. Maloney, Chronic Lyme Disease: An EvidenceBased Definition by the ILADS Working Group, ANTIBIOTICS, Dec. 16, 2019, at 1, 1–2 [hereinafter
An Evidence-Based Definition].
50. See Lawrence Zemel & Paul G. Auwaerter, Treating ‘Chronic Lyme Disease:’ Is it Medical
Fraud?, CT MIRROR (Dec. 13, 2019), https://ctmirror.org/category/ct-viewpoints/treating-chroniclyme-disease-is-it-medical-fraud-lawrence-zemel/ [https://perma.cc/Q6R4-NPHG].
51. See Controversies & Challenges in Treating Lyme and Other Tick-Borne Diseases, INT’L.
LYME & ASSOCIATED DISEASES SOC’Y, https://www.ilads.org/research-literature/controversieschallenges/ [https://perma.cc/73AZ-FM7C].
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A. The Infectious Diseases Society of America
The IDSA produces guidelines on Lyme disease treatment for early
stages of the disease but restricts diagnosis and treatment in many ways by
limiting the freedom of prescribing doctors and offering few options to
those patients who fail to improve after the initial round of treatment. First,
the 2006 IDSA Guidelines instruct doctors not to treat patients for Lyme
disease without a rash or positive lab test.52 Even in cases of suspected
heart block caused by Lyme carditis, the authors urge “the clinical
manifestations of Lyme carditis are too nonspecific to warrant a purely
clinical diagnosis” because “[t]he vast majority of patients . . . are
seropositive at the time of presentation.”53 Yet, as illustrated in Dr.
Spector’s medical history above, heart block caused by Lyme disease is
entirely plausible, despite negative test results, and failure to treat early
can be catastrophic.
Second, the 2006 IDSA Guidelines restrict access to antibiotic
treatment by defining symptoms of fatigue, musculoskeletal pain, and
cognitive difficulties, which are present at least six months after antibiotic
treatment, as “post-Lyme disease syndrome” (PLDS) rather than chronic
Lyme disease and recommend against further antibiotic treatment.54 The
IDSA Guidelines attribute these symptoms to be “more related to the aches
and pains of daily living rather than to either Lyme disease or a tickborne
coinfection.”55 As a result, many patients who fail IDSA’s recommended
Lyme disease treatment are diagnosed with fibromyalgia or chronic
fatigue syndrome, which are diseases of unknown origins.56 Maya
Dusenbery, author of Doing Harm, argues “it’s hard not to see the
tendency to shift Lyme patients who failed to get better after antibiotic
treatment into these diagnostic categories as a way of dismissing them as
hysterics and hypochondriacs without coming right out and saying so.”57
Doctors who follow the IDSA Guidelines treat patients who do not recover
with palliative care, which is intended to treat symptoms only and cutoff
patients from further antibiotics, in direct contradiction to ILADS
guidance.58
52. See generally 2006 IDSA Guidelines, supra note 47, at 1089–90, 1101, 1107, 1108.
Throughout the document, the authors note that a purely clinical diagnosis should not be used.
53. Id. at 1108.
54. Id. at 1120–21 (“To date, there is no convincing biologic evidence for the existence of
symptomatic chronic [Lyme disease] infection among patients after receipt of recommended treatment
regimens for Lyme disease.”).
55. Id. at 1115.
56. MAYA DUSENBERY, DOING HARM: THE TRUTH ABOUT HOW BAD MEDICINE AND LAZY
SCIENCE LEAVE WOMEN DISMISSED, MISDIAGNOSED, AND SICK 287 (2018).
57. Id.
58. See 2014 ILADS Guidelines, supra note 48, at 1122.
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Third, the new 2020 IDSA Guidelines, which replaced the 2006
Guidelines, caution practitioners against testing for Lyme disease at all if
patients do not meet specific criteria because the IDSA fears patients will
test positive for Lyme disease when they might not have it.59 However, the
IDSA Guidelines fail to consider the opposite issue of false negatives:
those who in fact have Lyme disease, but test negative due to the
inaccuracy of the test. For example, the 2020 Guidelines recommend
against testing for Lyme disease in patients exhibiting symptoms of
Multiple Sclerosis; Parkinson’s; cognitive decline; psychiatric illness in
adults; or developmental, behavioral or psychiatric disorders in children,
although the IDSA notes this recommendation is weak and based off lowquality evidence.60 However, a patient survey conducted by
LymeDisease.org found 72% of survey respondents were originally
misdiagnosed with other illnesses such as a psychiatric disorder, Multiple
Sclerosis, learning disabilities, and Parkinson’s, and were later diagnosed
with Lyme disease.61 Thus the fear of false positives could exacerbate the
problem of misdiagnoses for people who have Lyme because doctors are
told not to test for Lyme unless certain strict criteria are met. In addition,
the 2020 IDSA Guidelines conclude patients with extended symptoms
most likely have other illnesses, such as rheumatoid arthritis or depression,
and should not be treated further with antibiotics.62 Again, this leaves
patients whose doctors follow the IDSA guidelines without a solution to
their continued medical issues.
The 2020 IDSA Guidelines emphasize three reasons not to extend
antibiotic treatment beyond the minimum amount, but each reason
contains flaws. First, it argues that there are no high-quality studies
showing persistent infection.63 Second, it argues that there is no clinical or
laboratory proof of persistent infection. Third, it argues that the extended
59. Paul M. Lantos, Jeffrey Rumbaugh, Linda K. Bockenstedt, Yngve T. Falck-Ytter, Maria E.
Aguero-Rosenfeld, Paul G. Auwaerter, Kelly Baldwin, Raveendhara R. Bannuru, Kiran K. Belani,
William R. Bowie, John A. Branda, David B. Clifford, Francis J. DiMario Jr., John J. Halperin, Peter
J. Krause, Valery Lavergne, Matthew H. Liang, H. Cody Meissner, Lise E. Nigrovic, James J. Nocton,
Mikala C. Osani, Amy A. Pruitt, Jane Rips, Lynda E. Rosenfeld, Margot L. Savoy, Sunil K. Sood,
Allen C. Steere, Franc Strle, Robert Sundel, Jean Tsao, Elizaveta E. Vaysbrot, Gary P. Wormser &
Lawrence S. Zemel, Clinical Practice Guidelines by the Infectious Diseases Society of America
(IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR):
2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease, 72 CLINICAL
INFECTIOUS DISEASES e1, e10 (2021). [hereinafter 2020 IDSA Guidelines] (“Because of this potential
for false positive results, clinicians should be selective when ordering tests in patients with a low
probability of Lyme disease.”).
60. Id. at e3–e4.
61. LYMEDISEASE.ORG,2019 CHART BOOK: MYLYMEDATA REGISTRY 18 (2019) [hereinafter
MYLYMEDATA REGISTRY].
62. 2020 IDSA Guidelines, supra note 59, at e36–e37.
63. Id. at e37.
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use of antibiotics is harmful for patients, such as infection of the IV
catheters.64 However, 700 studies conducted by ILADS researchers show
evidence of persistent infection after treatment, confirmed through PCR
testing;65 and at least four IV antibiotic studies show the risk of infection
of antibiotic IV catheters was no greater than that of an IV placebo.66 In
addition, scientific author, Mary Beth Pfeiffer, points to the fact that
compared to other “pharmaceuticals with alarming toxic side effects”
antibiotics are “among the safest [drugs] there are.”67 In contrast to the
IDSA, ILADS believes that doctors and patients should be able to weigh
the potential risks of harm caused by antibiotics versus the morbidity of
harm caused by persistent infection.68
The IDSA’s statement on the ineffectiveness of antibiotics after
failure of an initial course of antibiotics relies on a study by Mark
Klempner, an author of the 2006 IDSA Guidelines. The study aimed to
determine whether prolonged antibiotic treatment helped patients, but it
was cut short when the safety and monitoring board found no significant
improvement.69 During the trial, patients were given thirty days of IV
antibiotics followed by 200 milligrams of doxycycline for sixty days.70
The study found 55% of patients in the antibiotic groups improved while
53% in the placebo groups also improved.71 In contrast, 14% of the
antibiotic group reported a worse outcome compared to 19% of the control
group.72 From these results, Klempner concluded that Lyme disease
patients have “considerable impairment in their health-related quality of
life . . . . [However, t]he patients . . . did not have evidence of persistent
infection . . . .”73
Shortly after the publication of Klempner’s study, members of
ILADS reviewed the merits of the study and found multiple
methodological weaknesses, including: “patient selection bias, suboptimal antibiotic treatment regimes, faulty analysis and/or exclusion of
64. Id. at e36–e37.
65. Plaintiffs’ First Amended Complaint at 18, Torrey v. Infectious Diseases Soc’y of Am., No.
5:17-cv-00190-RWS (E.D. Tex. Mar. 25, 2019).
66. Raphael Stricker, Raphael Stricker, M.D. Speaking at IDSA LD Review Hearings July 30,
2009, YOUTUBE (July 6, 2015), https://youtu.be/BSxLfkoY8Po [https://perma.cc/H3MC-4C23] (Dr.
Raphael Stricker is a prominent Lyme-literate doctor).
67. MARY BETH PFEIFFER, LYME: THE FIRST EPIDEMIC OF CLIMATE CHANGE 37 (2018).
68. 2014 ILADS Guidelines, supra note 48, at 1122, 1104.
69. Mark S. Klempner, Linden T. Hu, Janine Evans, Christopher H. Schmid, Gary M.
Johnson, Richard P. Trevino, DeLona Norton, Lois Levy, Diane Wall, John McCall, Mark Kosinski
& Arthur Weinstein, Two Controlled Trials of Antibiotic Treatment in Patients with Persistent
Symptoms and a History of Lyme Disease, 345 NEW ENG. J. MED. 85, 85 (2001).
70. Id. at 86.
71. Id. at 88.
72. Id.
73. Id. at 91.
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data, and disregard for B. Burgdorferi microbiology and pathogenesis.”74
ILADS members noted many patients enrolled in the study had already
failed a similar treatment regimen.75 Furthermore, the dosage of
doxycycline was too low to help patients experiencing neurologic
symptoms, making it more likely that these patients would fail treatment
again.76 Finally, ILADS notes that Lyme disease patients often experience
a flare in symptoms known as a “herx” reaction77 from the initiation of
antibiotic therapy, which makes patients feel worse before they feel
better.78 Despite these shortcomings, the IDSA continues to cite
Klempner’s study in its 2020 Guidelines as proof that persistent symptoms
are not associated with persistent infection.79 The IDSA’s denial of
persistent symptoms is seen by many as the force behind insurance claim
denials for extended antibiotic therapy80 and emphasizes the need for
congressional intervention.
B. The International Lyme and Associated Diseases Society
ILADS offers an entirely different perspective on disease prognosis
and treatment. It defines chronic Lyme disease as “a multisystem illness
with a wide range of symptoms and/or signs that are either continuously
or intermittently present for a minimum of six months. The illness is the
result of an active and ongoing infection [of Lyme disease].”81 Thus, a
significant difference in ILADS Guidelines is the acknowledgment that
continued symptoms are likely the result of continued infection.
In 2014, ILADS produced its most recent guidelines for treatment,
emphasizing the importance of clinical judgment in the absence of strong
scientific evidence.82 For patients experiencing persistent symptoms,
74. Steven E. Phillips, Robert Bransfield, Virginia T. Sherr, Stephen Brand, Harold A. Smith,
Kathleen Dickson & Raphael Sticker, Evaluation of Antibiotic Treatment in Patients with Persistent
Symptoms of Lyme Disease: An ILADS Position Paper, 10, conference paper [hereinafter ILADS
Position Paper].
75. Id. at 6.
76. Id.
77. Formally known as a Jarisch-Herxheimer reaction, this flare in symptoms is attributed to
inflammation caused by bacteria die-off. Lonnie Marcum, Lyme Sci: The Dreaded JarischHerxheimer Reaction, LYMEDISEASE.ORG (July 31, 2017), https://www.lymedisease.org/lymesciherxing/ [https://perma.cc/9CV3-5LF7] (“According to Dr. Joseph Burrascano, Jr., for patients who
have chronic or late-stage Lyme, the worst reaction is typically around the fourth week of
treatment . . . .”).
78. ILADS Position Paper, supra note 74, at 8.
79. 2020 IDSA Guidelines, supra note 59, at e36 & n.377.
80. Why is Lyme Disease Not Covered by Insurance?, MED. BILL GURUS,
https://www.medicalbillgurus.com/2017/09/why-isnt-lyme-disease-covered-by-insurance/
[https://perma.cc/3MWF-8RMT]; UNITEDHEALTHCARE OXFORD CLINICAL POLICY, supra note 26;
Aetna Clinical Policy, supra note 26.
81. An Evidence-Based Definition, supra note 49, at 1.
82. 2014 ILADS Guidelines, supra note 48, at 1104.
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ILADS 2014 Guidelines emphasize the following: “Ongoing symptoms at
the completion of active therapy were associated with an increased risk of
long-term failure in some trials and therefore clinicians should not assume
that time alone will resolve symptoms.”83 The guidelines further
emphasize that individualized care should be taken in deciding whether to
continue antibiotic treatment by assessing the risks of treatment
complications along with the burden of the disease.84 Burdens of disease
include “the risks of continuing to suffer significant morbidity or
permitting a serious systemic infection to progress.”85 Due to the risk of
underlying persistent infection, ILADS Guidelines recommend against
palliative care, which treats the symptoms but not the underlying illness.86
Doctors who treat patients based on ILADS Guidelines are referred to as
Lyme-literate medical doctors and Lyme-literate naturopathic doctors,
who are licensed doctors trained in a range of medical backgrounds with
years of experience treating patients with Lyme disease.87
ILADS recently compiled a list of over 700 peer-reviewed studies
showing persistent infection caused by Lyme disease.88 This Note will
speak of three studies specifically. The first is a 2012 study involving
Rhesus monkeys, who were chosen as hosts to provide objective results
that are not possible in humans due to vague, non-specific symptoms, and
inaccurate blood tests.89 After the monkeys were infected with Lyme and
given a high dose of antibiotics, scientists found both Lyme RNA in tissue
samples, indicating live organisms, and Lyme bacteria, recovered from
sterile ticks feeding off monkeys post treatment.90 These discoveries
suggest the possibility of persistence in humans as well.91 Critics of animal
studies, including the IDSA, believe studies on animals cannot provide a
hypothesis for persistent infection in humans because animals do not
83. Id. at 1108.
84. Id. at 1109, 1122.
85. Id. at 1104.
86. Id. at 1122.
87. Shona Curley, What Is a Lyme-Literate Doctor, and How to Find the Right One, PROHEALTH
(Dec. 2, 2019), https://www.prohealth.com/library/what-is-a-lyme-literate-doctor-and-how-to-findthe-right-one-92738 [https://perma.cc/E6RL-M7AQ]; see also What Makes a Doctor Lyme Literate?,
IGENEX, https://igenex.com/tick-talk/what-makes-a-doctor-lyme-literate [https://perma.cc/9KMU23ET] [hereinafter What Makes a Doctor Lyme Literate?].
88. Plaintiffs’ First Amended Complaint, supra note 65, at 18.
89. Monica E. Embers, Stephen W. Barthold, Juan T. Borda, Lisa Bowers, Lara Doyle, Emir
Hodzic, Mary B. Jacobs, Nicole R. Hasenkampf, Dale S. Martin, Sukanya Narasimhan, Kathrine M.
Phillippi-Falkenstein, Jeanette E. Purcell, Marion S. Ratterree & Mario T. Philipp, Persistence of
Borrelia Burgdorferi in Rhesus Macaques Following Antibiotic Treatment of Disseminated Infection,
PLOS ONE, Jan. 11, 2012, at 1, 1–2 (Rhesus monkeys specifically were chosen because they manifest
many of the same symptoms as humans with Lyme disease).
90. Id. at 6.
91. Id. at 8.
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match the biology of humans and cannot show human fatigue or pain.92
However, animal studies are likely the only way to show large scale
unified results for Lyme disease because conducting similar studies that
require withholding antibiotic therapy from human patients would be
unethical.93
A second study found Lyme spirochetal clusters as well as Lyme
DNA sequences in multiple organ samples from a deceased patient who
received approximately sixteen years of extensive antibiotic treatment.94
The study produced “several lines of evidence that suggest that [Lyme
disease] can persist in the human body,” despite years of antibiotic
treatment and may be the cause of persistent symptoms.95
A third retrospective human study cultured Lyme spirochetes from
three patients with persistent symptoms who had previously undergone
months of antibiotic therapy, contradicting IDSA Guidelines in three
ways. 96 First, the patients lived in Georgia and Florida, which are not
endemic regions according to the IDSA Guidelines.97 Second, each patient
tested negative for Lyme disease using the CDC-approved antibody blood
test, pointing to the inaccuracy of antibody testing.98 Third, each patient
underwent antibiotic therapy previously but were still culture positive,
proving that bacteria persisted after initial treatment.99
Because reaching a consensus on the cause and proper treatment of
persistent infection could be decades away, federal legislation is needed to
help patients currently struggling with the financial burden of Lyme
disease. Patients whose doctors decide to treat persistent infection
92. 2020 IDSA Guidelines, supra note 59, at e36.
93. See Marcus Davidsson, The Financial Implications of a Well-Hidden and Ignored Chronic
Lyme Disease Pandemic, HEALTHCARE, Feb. 13, 2018, at 1, 41–42; see also Cameron, supra note 31,
at 470–72.
94. Eva Sapi, Rumanah S. Kasliwala, Hebo Ismail, Jason P. Torres, Michael Oldakowski, Sarah
Markland, Gauri Gaur, Anthony Melillo, Klaus Eisendle, Kenneth B. Liegner, Jenny Libien & James
E. Goldman, The Long-Term Persistence of Borrelia Burgdorferi Antigens and DNA in the Tissues of
a Patient with Lyme Disease, ANTIBIOTICS, Oct. 11, 2019, at 1, 1.
95. Id. at 1, 19.
96. N. Rudenko, M. Golovchenko, M. Vancova, K. Clark, L. Grubhoffer & J. H. Oliver, Jr.,
Isolation of Live Borrelia Burgdorferi Sensu Lato Spirochaetes from Patients with Undefined
Disorders and Symptoms Not Typical for Lyme Borreliosis, 22 CLINICAL MICROBIOLOGY &
INFECTION 267.e9, 267.e11–12 (2016) [hereinafter Isolation of Live Borrelia Burgdorferi]; see also
PFEIFFER, supra note 67, at 150-53.
97. Isolation of Live Borrelia Burgdorferi, supra note 96, at 267.e11–12. The IDSA lists three
endemic regions in its Guidelines: the Northeast, from Virginia through eastern Canada; the upper
Midwest; and Northern California. 2020 IDSA Guidelines, supra note 59, at e6; see also PFEIFFER,
supra note 67, at 151.
98. Isolation of Live Borrelia Burgdorferi, supra note 96, at 267.e11–12; see also PFEIFFER, supra
note 67, at 151–52.
99. Isolation of Live Borrelia Burgdorferi, supra note 96, at 267.e11-12; see also PFEIFFER, supra
note 67, at 152.
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according to ILADS Guidelines should have a right to receive insurance
coverage for their medical expenses, just as they would if their doctors
followed IDSA Guidelines.
III. LEGAL ISSUES
A. IDSA Anti-Trust Claims
In 2007, former Connecticut Attorney General, Richard Blumenthal,
investigated the IDSA for potential antitrust law violations associated with
the IDSA’s 2006 Guidelines. Three factors significant to the antitrust
claims included the following: (1) the exclusion of IDSA members on the
guidelines panel who had opposing views on how to treat chronic Lyme
disease;100 (2) the reliance by medical societies, government agencies, and
insurance companies on the IDSA Guidelines, which they view as
mandatory because the Guidelines do not provide treatment alternatives or
allow for clinical judgment; and (3) the strong influence IDSA has over
medical journals, hospitals, and medical boards.101 The combination of
these three factors has the effect of excluding doctors who treat patients
using the alternative guidelines.102 In 2008, Blumenthal concluded his
investigation, stating:
The IDSA’s 2006 Lyme disease guideline panel undercuts its
credibility by allowing individuals with financial interests–in drug
companies, Lyme disease diagnostic tests, patents and consulting
arrangements with insurance companies–to exclude divergent
medical evidence and opinion. In today’s healthcare system, clinical
practice guidelines have tremendous influence on the marketing of
medical services and products, insurance reimbursements and
treatment decisions. As a result, medical societies that publish such
guidelines have a legal and moral duty to use exacting safeguards and
scientific standards.103

As a result of the investigation, the IDSA entered into an agreement
with the Connecticut Attorney General’s Office to form an independent
100. Lorraine Johnson & Raphael B. Stricker, Attorney General Forces Infectious Diseases
Society of America to Redo Lyme Guidelines Due to Flawed Development Process, 35 J. MED. ETHICS
283, 284 (2009) (“In its previous guidelines panel, IDSA summarily tossed off the panel one researcher
who disagreed with the panel chair on the best approach for treatment of chronic Lyme disease.”); see
also Lorraine Johnson & Raphael B. Stricker, The Infectious Diseases Society of America Lyme
Guidelines: A Cautionary Tale About the Development of Clinical Practice Guidelines, PHIL., ETHICS,
& HUMANS. MED., 2010, at 1, 3 [hereinafter A Cautionary Tale].
101. A Cautionary Tale, supra note 100, at 1–3.
102. Id. at 1–3.
103. Press Release, Richard Blumenthal, State of Conn. Att’y Gen., Attorney General’s
Investigation Reveals Flawed Lyme Disease Guideline Process, IDSA Agrees to Reassess Guidelines,
Install Independent Arbiter (May 1, 2008) (on file with author).
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review panel to assess the need for revision of the guidelines.104 In 2010,
a final report by the IDSA panel, consisting exclusively of IDSA
members,105 found revision of the guidelines to be unnecessary.106 While
the agreement by the attorney general’s office was laudable, the lack of
third party review of the IDSA Guidelines allowed the IDSA to continue
its questionable behavior without oversight and thus allowed insurance
companies to continue denying treatment to those who did not follow the
IDSA Guidelines.
Despite the analysis by the 2010 review panel, the 2006 IDSA
Guidelines continue to receive considerable pushback. In 2016, the
National Guidelines Clearinghouse removed the guidelines from their
database because the guidelines did not meet the Institute of Medicine’s
standards.107 Then, in 2017, the link to the guidelines was removed from
the CDC’s website.108 Lyme disease activists further point to flaws in the
IDSA treatment method. Lorraine Johnson, CEO of LymeDisease.org, and
Dr. Raphael B. Stricker explain:
There have been no trials demonstrating the efficacy of the 30-day
antibiotic treatment duration[; t]here is currently no diagnostic test
that can establish the eradication of B. burgdorferi[; and t]here is no
evidence to support the hypothesis that the sole cause of the
continuing symptoms is the presence of immune complexes.109

Federal legislation requiring treatment coverage based on ILADS
Guidelines is therefore important because the IDSA may resist changing
its guidelines due to potential exposure to malpractice liability. As Dr.
Kenneth Liegner states: “[I]f [IDSA doctors] acknowledge they are wrong,
they are liable for medical neglect–for failure to diagnose and failure to
treat. So[,] they are doing the only thing they can–denying that chronic
Lyme disease even exists.”110 There are many hypotheses as to why the
IDSA refuses to acknowledge the existence of chronic Lyme disease, from

104. An Agreement Between the Attorney General of the State of Connecticut and the Infectious
Diseases Society of America 1, 1 (April 30, 2008) (on file with author).
105. Lorraine Johnson, IDSA Lyme Guidelines Removed from NGC; ILADS Guidelines Still
There, LYMEDISEASE.ORG (Feb. 12, 2016), https://www.lymedisease.org/idsa-guidelines-removedngc/ [https://perma.cc/4W9G-54G2] [hereinafter IDSA Lyme Guidelines Removed].
106. Paul M. Lantos, William A. Charini, Gerald Medoff, Manuel H. Moro, David M. Mushatt,
Jeffrey Parsonnet, John W. Sanders & Carol J. Baker, Final Report of the Lyme Disease Review Panel
of the Infectious Diseases Society of America, 51 CLINICAL INFECTIOUS DISEASES 1, 1 (2010).
107. IDSA Lyme Guidelines Removed, supra note 105.
108. Dorothy Kupcha Leland, CDC Website Removes Link to IDSA Guidelines. Just Lipstick on
a Pig?, LYMEDISEASE.ORG (Dec. 2, 2017), https://www.lymedisease.org/touchedbylyme-cdclipstick-on-pig/ [https://perma.cc/REM3-2YXV].
109. Medicolegal Assessment, supra note 41, at 537.
110. WEINTRAUB, supra note 18, at 141.
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fear of malpractice to deals with insurance companies, as outlined in Part
III.B.
B. Does the IDSA Conspire with Insurance Companies?
Insurance companies presumably support the IDSA Guidelines
because the guidelines restrict treatment and thus reduce the overall
expense of Lyme disease for insurance companies. In the lawsuit Torrey
v. IDSA, filed by patients against the IDSA and eight insurance companies,
plaintiffs claim that the IDSA and the insurance companies worked in
collusion to deny antibiotic treatment to chronic Lyme disease patients.111
In their second amended complaint, the plaintiffs alleged that defendants
violated antitrust laws by:
(1) denying the existence of chronic Lyme disease, (2) condemning
the use of long-term antibiotics, (3) allowing doctors who treat
chronic Lyme patients to be sanctioned by medical boards, and (4)
using the guidelines as a basis to deny insurance coverage of chronic
Lyme treatments. The power of the IDSA, the IDSA Panelists, and
the Settling Insurance Companies restrains trade, therefore, the IDSA
guidelines have significantly reduced the Lyme treatment market.112

As a result, the plaintiffs claim they, along with all others suffering
from Lyme disease, were wrongfully deprived of proper diagnosis,
treatment, and insurance coverage.113 Since the initiation of the case, all
eight insurance companies settled with the plaintiffs.114 Although the judge
dismissed both the RICO and antitrust claims citing lack of evidence of a
conspiring agreement,115 plaintiffs filed a notice of appeal to the Fifth
Circuit in regards to their negligent and fraudulent misrepresentation
claims.116

111. See Plaintiffs’ Second Amended Complaint at 7–9, Torrey v. Infectious Diseases Soc’y of
Am., No. 5:17-cv-00190-RWS (E.D. Tex. Jan. 7, 2021); see also Mary Beth Pfeiffer, A Lawsuit on
Behalf
of
Lyme
Disease
Patients,
FIRST
EPIDEMIC
(June
1,
2021),
https://www.thefirstepidemic.com/lyme-lawsuit-1 [https://perma.cc/GZ23-FGVT] [hereinafter A
Lawsuit on Behalf of Lyme Disease Patients].
112. Plaintiffs’ Second Amended Complaint, supra note 111, at 31; see also A Lawsuit on Behalf
of Lyme Disease Patients, supra note 111.
113. Plaintiffs’ Second Amended Complaint, supra note 111, at 12.
114. Plaintiffs’ Second Amended Complaint, supra note 111, at 3; A Lawsuit on Behalf of Lyme
Disease Patients, supra note 111.
115. Order at 1, 16–19, Torrey v. Infectious Diseases Soc’y of Am., No. 5:17-cv-00190-RWS
(E.D. Tex. Sept. 1, 2021).
116. Plaintiffs’ Notice of Appeal at 1, Torrey v. Infectious Diseases Soc’y of Am., No. 5:17-cv00190-RWS (E.D. Tex. Oct. 19, 2021); A Lawsuit on Behalf of Lyme Disease Patients, supra note 111.
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C. Insurance Companies Target Lyme-Literate Doctors; State Laws Aim
to Protect Them
Although reporting to medical boards is anonymous, the plaintiffs in
Torrey v. IDSA and others believe “[m]any of the doctors . . . are reported
by insurance companies” to reduce the number of physicians willing to
treat chronic Lyme disease.117 As a result of this threat by medical boards
and insurance companies, many doctors have left the field, forcing chronic
Lyme disease patients, desperate for care, to travel hundreds of miles for
treatment.118
Dr. William Brown of Portland, Oregon was one of the first
physicians to be targeted by an insurance company in 1994, when a
reviewer from an HMO insurance company reported Brown to Oregon’s
Board of Medical Examiners.119 Despite the fact that five of the six patients
included in the investigation showed drastic improvement based on his
prescribed treatment, the Medical Board permitted Brown to continue
practicing medicine only if he agreed to stop treating Lyme disease
patients.120
In 1993, Dr. Joseph Burrascano, Jr., a Lyme-literate doctor who was
one of the first to treat patients for Lyme disease in Long Island, testified
to the Senate that:
There is in this country a core group of university-based Lyme
disease researchers and physicians whose opinions carry a great deal
of weight. Unfortunately, many of them act unscientifically and
unethically. They adhere to outdated, self-serving views and attempt
to personally discredit those whose opinions differ from their own.
They exert strong, ethically questionable influence on medical
journals, which enables them to publish and promote articles that are
badly flawed. They work with Government agencies to bias the
agenda of consensus meetings and have worked to exclude from these
meetings and scientific seminars those with [alternate] opinions….
117. Plaintiffs’ Second Amended Complaint, supra note 111, at 12, 16; See also LIEGNER, supra
note 11, at 784–85.
118. See e.g., Relating to Lyme Disease; and Declaring an Emergency: Hearing on S.B. 916
Before the H. Comm. on Health Care, 2015 Leg., 78th Sess. 3 (Or. 2015) (statement of Marty Ross)
(“I have a number of colleagues in California and Washington State who treat Oregonians because
care is not available in state.”). Dr. Marty Ross was personally targeted by the medical board in
Washington state in 2018, yet no violations were found, and he resumed practice in late 2019. Marty
Ross, Story: Passion. Experience. Service. Compassion. We Get It., MARTY ROSS MD HEALING ARTS,
https://martyrossmd.com/story [https://perma.cc/94SP-6M9C].
119. WEINTRAUB, supra note 18, at 223; see also Phyllis Mervine, Threat of Disciplinary Action
Creates
Tense
Atmosphere
for
Lyme
Docs,
LYME
TIMES
(Oct.
1994),
https://www.lymenet.org/newsletter/deet/domino/nl.nsf/b18db4ad8571a779852565e3007d9d16/996
155967e71fb8f852565e30012f1c0_OpenDocument [https://perma.cc/W33Q-QRF3].
120. WEINTRAUB, supra note 18, at 223–24.
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And indeed, I have to confess that today I feel that I am taking a
personal risk, a large one, because I am stating these views publicly,
for fear that I may suffer some repercussions despite the fact that
many hundreds of physicians and many thousands of patients all over
the world agree with what I am saying here today.121

As Dr. Joseph Burrascano predicted, the medical board of New York
opened an investigation shortly thereafter.122 In 2001, thirty-seven of the
thirty-nine charges123 against him were cleared and the state medical
board’s hearing committee admitted: “The issues raised in this case
pertained primarily to a medical debate in this field, rather than a
demonstrated lack of competency by the Respondent.”124 The committee
further noted, “We are . . . acutely aware that it was not this Committee’s
role to resolve this medical debate . . . .”125 In response to this
investigation, and similar investigations of other Lyme-literate doctors,
eight states have passed laws to protect doctors who treat patients with
antibiotics for more than twenty-eight days.126
In 2002, the New York State Assembly adopted Resolution 2155
stating:
WHEREAS, Insurance companies can and do file complaints with
the New York State office of Professional Medical Conduct against
doctors who treat chronic Lyme disease, and have thus injected
themselves into the debate; and WHEREAS, Doctors . . . who
continue to provide treatment if they feel such treatment is medically
necessary, have noted significant improvement in the condition of
their patients . . . . [T]his Legislative Body . . . request[s] that
insurance companies and the Office of Professional Medical Conduct
cease and desist from targeting physicians . . . until such time as
121. Lyme Disease: A Diagnostic and Treatment Dilemma: Hearing on Examining the Adequacy
of Current Diagnostic Measures and Research Activities in the Prevention and Treatment of
Lyme Disease Before the Comm. on Lab. & Hum. Res., 103rd Cong. 54–55, 57–58 (1993)
[hereinafter 1993 Senate Hearing] (statement of Dr. Joseph Burrascano, Jr.). For more
information on the history of Lyme disease and Dr. Burrascano’s role, see ILADS, 2018 ILADS
Webinar–History of Lyme Disease by Joseph Burrascano, Jr. MD, VIMEO (Dec. 18, 2018),
https://vimeo.com/306846706 [https://perma.cc/677Y-RRMS].
122. WEINTRAUB, supra note 18, at 228–32.
123. Of the two remaining charges, one related to treating a patient for Ehrlichia, who did not
have the specific symptoms, despite positive blood test results. The second was for failure to stop a
medication after a patient experienced a seizure, even though the patient had seizures prior to using
the medication. Id. at 232.
124. Joseph Burrascano, M.D., 265 B.P.M.C. 1, 43 (2001) (Levin, Arb.); see also WEINTRAUB,
supra note 18, at 232.
125. Joseph Burrascano, M.D., 265 B.P.M.C. 42; See also WEINTRAUB, supra note 18, at 232.
126. See CAL. BUS. & PROF. CODE § 2234.1 (2006); CONN. GEN. STAT. § 20-14m (2021); 225
ILL. COMP. STAT. § 60/22(c) (2021); IOWA CODE § 147.56 (2017); MD. CODE, HEALTH OCC. § 1-604
(2020); MASS. GEN. LAWS ch. 112, § 12DD (2010); ME. REV. STAT. tit. 32, § 3282-B (2015); 5 R.I.
GEN. LAWS § 5-37.5-4 (2020).
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medical research and the medical community have determined the
appropriate parameters for the diagnosis and treatment of tick-borne
illnesses . . . .127

Illinois law offers an example of state legislation aimed at protecting
Lyme-literate doctors.128 Specifically, it states:
The Department shall not revoke, suspend, place on probation,
reprimand, refuse to issue or renew, or take any other disciplinary or
non-disciplinary action against the license or permit issued under this
Act to practice medicine to a physician… for experimental treatment
for Lyme disease or other tick-borne diseases, including, but not
limited to, the prescription of or treatment with long-term
antibiotics.129

The Illinois law is effective because it is broad in scope, allows for
any type of experimental treatment, and does not allow the state medical
board to revoke licensure solely for prescribing long-term antibiotics.
Legal scholar, Creighton Meland, argues that despite minor flaws existing
in state laws offering physician protection for Lyme-literate doctors, such
laws are exceedingly important in helping doctors who provide care to
those who are chronically ill.130
Opponents to legislative action protecting Lyme-literate doctors
claim Lyme disease activists “spurred legislative efforts to subvert
evidence-based medicine and peer-reviewed science,”131 and argue that
legislation allowing for the extended use of antibiotic treatment will lead
to antibiotic resistance.132 However, opponents fail to acknowledge flaws
in IDSA’s own “evidenced based science,” as explored in Part I. And,
while antibiotic resistance is a serious issue, the CDC does not list the
treatment of Lyme disease as a factor leading to resistance.133 Meanwhile,
127. Assemb. Res. 2155, 225th Ann. Sess. (N.Y. 2002); Plaintiffs’ Second Amended Complaint,
supra note 111, at 13.
128. Id.
129. 225 ILL. COMP. STAT. § 60/22(c) (2021).
130. Creighton R. Meland, Jr., They Shall Not Be Left to Rot: The Emerging Law of Lyme
Disease, 8 BELMONT L. REV. 95, 159 (2020).
131. Paul G. Auwaerter, Johan S. Bakken, Raymond J. Dattwyler, J. Stephen Dumler, John J.
Halperin, Edward McSweegan, Robert B. Nadelman, Susan O’Connell, Eugene D. Shapiro, Sunil K.
Sood, Allen C. Steere, Arthur Weinstein & Gary P. Wormser, Antiscience and Ethical Concerns
Associated with Advocacy of Lyme Disease, 11 LANCET INFECTIOUS DISEASES 713, 713 (2011).
132. See generally Joseph B. Franklin, Note, Antibiotic Maximalism: Legislative Assaults on the
Evidence-Based Treatment of Lyme Disease, 90 WASH. U. L. REV. 199 (2012).
133. See CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN
THE UNITED STATES 64 (rev. 2019). See also Meland, supra note 130, at 160–61. Not to mention the
fact that antibiotics are commonly used in our food stream, which does lead to antibiotic resistant
bacteria. See Celeste Robb-Nicholson, By the Way, Doctor: Are the Antibiotics in Poultry Dangerous?,
HARVARD
HEALTH
PUBL’G
(Mar.
2014),
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activists around the country continue to push for additional state
legislation to protect doctors and increase access to care.
IV. THE COST OF LYME DISEASE
A. The Cost of Limited Government Funding
One of the major obstacles to uncovering the cause of chronic Lyme
disease and finding a cure is the lack of government funding for research
as compared to other vector-borne diseases.134 In 1993, the U.S. Senate
Committee on Labor and Human Resources held a hearing entitled: Lyme
Disease: A Diagnostic and Treatment Dilemma.135 After hearing patient
stories, Senator Bill Bradley noted: “This is an enormous national problem
that we are refusing to address . . . . NIH has to get its act together . . . .”136
Senator Metzenbaum followed, stating:
I think [the testifying constituents] have sounded a clarion call that
we ought to get off our butts and do something about this. Frankly, I
think it is an illness that has been swept under the carpet, and not
many people have paid attention to it…. I have heard of Lyme
disease, but it hasn’t struck me with the strength of your testimony
today.137

Yet, despite the Senators’ concerns, it appears Congress did little to
help.
A few years later in 1998, Senator Christopher J. Dodd of
Connecticut highlighted the issue in his proposal for a $3 million
amendment to the Department of Defense budget for Lyme disease
research, stating “[l]ong term treatment expenses can exceed $100,000 per
person—a phenomenal cost to society. But an even greater price is paid
by the victims and their families. We can put no price tag on the emotional
costs associated with this disease.” 138 And in relation to the military, he
noted: “The growing number of cases has led the Department of Defense
to recognize that Lyme Disease and other tick-borne illnesses pose a
potentially serious health threat to our troops, civilian employees, and
residents at military installations all over the world—and thus a threat to
https://www.health.harvard.edu/newsletter_article/By_the_way_doctor_Are_the_antibiotics_in_poul
try_dangerous [https://perma.cc/3JWY-U3X3].
134. Vector-borne diseases are caused by parasites, viruses, and bacteria that are typically
transmitted to humans via blood sucking insects. Vector-Borne Diseases, WORLD HEALTH ORG. (Mar.
2,
2020),
https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases
[https://perma.cc/EPL3-Q6SP].
135. 1993 Senate Hearing, supra note 121, at 1.
136. Id. at 39 (statement of Sen. Bill Bradley).
137. Id. at 51 (statement of Sen. Howard Metzenbaum).
138. 105 CONG. REC. S7,136 (daily ed. June 25, 1998) (statement of Sen. Christopher Dodd).
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our military readiness.”139 Yet, as of today, Lyme disease is missing from
the U.S. Wartime Disability Compensation Statute.140
By 2019, little had changed in terms of government assistance in
finding a cure for Lyme disease. The CDC estimates around 476,000
Americans are diagnosed with Lyme disease each year, yet the NIH
dedicated only $32 million to research the disease in 2019.141 In contrast,
the CDC estimates only 2,000 U.S. residents are infected with malaria
each year, and most cases are from travelers abroad.142 But the NIH spent
$254 million on research for malaria and the malaria vaccine.143 Breaking
the research dollars down by diagnosis shows the NIH spent $127,000 in
research for each malaria diagnosis in 2019 and only $67 for each Lyme
disease diagnosis.144
The Kay Hagan Tick Act, passed in 2019 and the Omnibus
Appropriations bill of 2021 expand research funding but do so with a
caveat and provide little help to those currently suffering from the disease.
The Kay Hagan Tick Act provides $10 million for new centers for
excellence in vector-borne diseases and $20 million for enhanced support
for health departments.145 But before passing the bill, senators removed all
mention of the word “Lyme” and removed the requirement for
proportional funding based on the disease burden in the U.S., which would
have made Lyme disease first in line for funding.146 As a result activists
fear a larger portion of the funding will now go to other vector-borne
illnesses like Zika, Malaria, and West Nile Virus, which have received
more funding than Lyme disease in past years.147 The Fiscal Year 2021

139. Id.
140. See 38 U.S.C. § 1112. Although chronic disease and tropical diseases are covered, it is
likely that Lyme disease patients fall through the cracks because the CDC fails to recognize Lyme
disease as a chronic illness. Jenna Luché-Thayer, former Senior Advisor to the U.S. Government and
United Nations and author of $lyme, reasons “[c]ost containment and liability may be a forceful reason
behind the government downplay of persistent infection that requires ongoing care.” Jenna LuchéThayer, Seventy Post Treatment Lyme Disease Syndrome Publications Ignore Infection, LINKEDIN
(Aug. 14, 2020), https://www.linkedin.com/pulse/seventy-post-treatment-lyme-disease-syndromeignore-luche-thayer/ [https://perma.cc/5YNL-QFAN].
141. How Many People Get Lyme Disease?, supra note 21; NIH Estimates of Funding, supra
note 23.
142. About Malaria, supra note 24.
143. NIH Estimates of Funding, supra note 23.
144. ($254 million ÷ 2,000 cases = $127,000); ($32 million ÷ 476,000 cases = $67).
145. Kay Hagan Tick Act, sec. 404, 133 Stat. 3116-17 (2019) (codified as 42 U.S.C. § 247b-23).
146. Important Information You Need to Know About the Tick Act, LYME DISEASE ASS’N. (Nov.
20,
2019),
https://lymediseaseassociation.org/government/federal-government/importantinformation-you-need-to-know-about-the-tick-act/ [https://perma.cc/R4DZ-K8YR].
147. Id.; NIH Estimates of Funding, supra note 24; see Zika Virus – Digital Media Kit, NAT’L
INST.
HEALTH,
https://www.nih.gov/news-events/zika-virus-digital-mediakit#:~:text=Funding%20for%20Zika%20Research,-
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Omnibus Appropriations bill requires an additional $10 million be spent
on Lyme disease research on top of the $53 million proposed by the NIH,
which is the most funding provided for Lyme disease research in years.148
But while additional funding for research is instrumental to future
diagnosis and treatment, and is long overdue, research funding does little
to help patients currently suffering from chronic Lyme disease who
continue to face high costs for treatment and insurance coverage denials.
B. The Cost of Limited Insurance Coverage
For patients, frequent outpatient visits and expensive medications
attribute to the high cost of Lyme disease treatment, which is exacerbated
by insurance claim denials.149 Direct medical costs for treatment of Lyme
disease are estimated to be between $712 million and $1.3 billion a year
in the U.S.150 From an individual cost perspective, patients with Lyme
disease incur $2,968 more in medical expenses each year than the average
insured person without Lyme disease and patients with one or more
chronic symptom spend $3,798 more than Lyme patients without chronic
symptoms.151 The high cost of treatment, particularly IV antibiotics, meant
Lyme disease became a financial burden for insurance companies
beginning in the 1990s.152 To alleviate the burden on the insurance
companies’ bottom line, many companies began tightening requirements
for proof of illness.153 For example, some began requiring patients to meet
the CDC surveillance criteria before providing coverage, despite the
CDC’s warning that its surveillance criteria should not be used for
diagnosis due to its strict requirements.154
Currently, patients are forced to incur treatment expenses because
insurance companies pre-define what treatment is medically necessary.
Zika%20virus%20does&text=In%20FY%202017%20NIAID%20obligated,5325
[https://perma.cc/T2LY-3EGD].
148. Bonnie Crater, Historic Increase in Lyme Funding Passes Congress: Now Goes to
President, LYMEDISEASE.ORG (Dec. 27, 2020), https://www.lymedisease.org/historic-increase-inlyme-funding/ [https://perma.cc/HVG3-HUVC].
149. 2ND REPORT TO CONGRESS, supra note 25, at 63.
150. Emily R. Adrion, John Aucott, Klaus W. Lemke & Johnathan P. Weiner, Health Care Costs,
Utilization and Patterns of Care Following Lyme Disease, PLOS ONE, Feb. 4, 2015, at 1, 12.
151. Id. at 1–2.
152. WEINTRAUB, supra note 18, at 303–04.
153. Id.
154. Id. at 304; see also Chronic Lyme Disease and Long-Term Antibiotic Treatment: Hearing
Before the Assemb. Standing Comm. on Health, 2001 Leg., 224th Ann. Sess. 16 (N.Y. 2001)
(statement of Patricia Smith) [hereinafter Chronic Lyme Hearing NY]; Lyme Disease (Borrelia
burgdorferi) 2017 Case Definition, CTRS. DISEASE CONTROL & PREVENTION (Apr. 16, 2021),
https://ndc.services.cdc.gov/case-definitions/lyme-disease-2017/
[https://perma.cc/RX4W-T5SK]
(“Surveillance case definitions are not intended to be used by healthcare providers for making a
clinical diagnosis or determining how to meet an individual patient’s health needs.”).
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United Healthcare Oxford’s current clinical policy lists IV antibiotic
treatment for Lyme disease as “not medically necessary” for patients with
the policy’s defined Post-Treatment Lyme Disease Syndrome (PTLDS).155
It defines PTLDS as “Fatigue, [w]idespread musculoskeletal pain[, and
c]omplaints of cognitive difficulties” if the symptoms persist more than
six months after antibiotic treatment.156 Similarly, Aetna lists treatment for
PTLDS as “experimental” and “investigational.”157 By defining treatment
as “experimental” or “investigatory,” insurance companies narrowly craft
definitions within their contracts and refuse to pay for treatment.158
Patients do have some power to push back through internal appeals
and civil lawsuits, but the process is costly and may require patients to
wait for pre-authorization without treatment. Further, judges are often put
in the position of determining medical necessity.159 Under the Employee
Retirement Income Security Act (ERISA),160 for example, a patient can
bring a civil suit after internal appeal for denial of benefits.161 However,
leaving it up to the courts to decide whether a treatment is medically
necessary can be ineffective, time consuming, and, for cases raised in
different jurisdictions, inconsistent.162 With diseases such as Lyme that are
still under considerable medical debate, courts may be forced to decide
between one medical expert who deems the treatment experimental, and
another who states the opposite.163 Meanwhile, the patient will continue
to suffer symptoms, which can worsen over time without treatment. In
Fuja v. Benefit Trust Life Insurance Co., a case about whether a certain
breast cancer treatment could be denied insurance coverage because the
treatment was pursued “in connection with medical or other research”164
the court stated:
[C]ases of this nature pose troubling social as well as ethical
questions that go well beyond the legal issues. As a court of law[,]
we are empowered to decide legal issues presented by specific cases
155. UNITEDHEALTHCARE OXFORD CLINICAL POLICY, supra note 26, at 1.
156. Id. at 2.
157. Aetna Clinical Policy, supra note 26.
158. See Angela R. Holder, Funding Innovative Medical Treatment, 57 ALB. L. REV. 795, 796
(1994).
159. Sharona Hoffman, A Proposal for Federal Legislation to Address Health Insurance
Coverage for Experimental and Investigational Treatments, 78 OR. L. REV. 203, 220 (1999).
160. ERISA “sets minimum standards for most voluntarily established retirement and health
plans in private industry to provide protection for individuals in these plans.” ERISA, U.S. DEP. LAB.,
https://www.dol.gov/general/topic/healthplans/erisa#:~:text=The%20Employee%20Retirement%20Income%20Security,for%20individuals%
20in%20these%20plans [https://perma.cc/N9BT-F2JU].
161. 29 U.S.C. § 1132(a)(1)(B).
162. Hoffman, supra note 159, at 218–19.
163. Fuja v. Benefit Tr. Life Ins. Co., 18 F.3d 1405, 1412 (7th Cir. 1994).
164. Id. at 1409. See also Hoffman, supra note 159, at 209.
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or controversies. The greater social questions must be decided by the
political branches of government which can engage in “legislative
fact-finding” and “benefit from public hearings and constituent
expression of opinion.”165

Thus, some judges argue that the medical coverage debate is best left
to the legislators instead of the courts.
Legislation offers the best hope for patients to receive reimbursement
for their treatment from insurance companies. A law can uniformly
prevent unfair denial of treatment based on poor scientific studies, such as
Klempner’s study,166 and will remove the delay caused by the appeal
process. Finally, federal legislation will reduce the burden on judges, who
are currently forced to decide on social and ethical issues well outside the
scope of legal issues.
V. STATES THAT MANDATE INSURANCE COVERAGE FOR LYME
TREATMENT
Eight states have passed legislation specific to insurance coverage
for Lyme disease.167 In addition, Pennsylvania, New Jersey, and New York
have recently proposed legislation to mandate insurance coverage.168 This
Part will briefly discuss the positive and negative aspects of current state
legislation beginning with Connecticut, which requires:
Each individual health insurance policy… shall provide coverage for
Lyme disease treatment including not less than thirty days of
intravenous antibiotic therapy, sixty days of oral antibiotic therapy,
or both, and shall provide further treatment if recommended by a
board certified rheumatologist, infectious disease specialist or
neurologist…. 169

The issue with the law as written, however, is that most Lyme-literate
doctors who treat chronic Lyme disease are not certified in the
165. Fuja, 18 F.3d at 1412 (quoting Wangen v. Ford Motor Co., 294 N.W.2d 437, 469 (Wis.
1980) (Coffey, J., dissenting)).
166. See supra Part II.
167. CONN. GEN. STAT. § 38a-492h (2000); 215 ILL. COMP. STAT. 5/356z.33 (2020); MASS.
GEN. LAWS ch. 175, § 47HH (2017); ME. REV. STAT. tit. 24-A, § 4302 (2019); MINN. STAT. § 62A.265
(1996); N.H. REV. STAT. § 415:18-ee (2021); R.I. GEN. LAWS § 5-37.5-5 (2004); R.I. GEN. LAWS §
27-18-62 (2004); W. VA. CODE § 33-6-38 (2018); see also Michelle Treseler, Advocacy Q&A,
YOUTUBE
(Oct.
29,
2021),
https://www.youtube.com/watch?v=bPby5kvqm04
[https://perma.cc/887E-FXNR] (Ms. Treseler speaks about many of the state Lyme insurance laws in
this video).
168. H.B. 1033, 205th Gen. Assemb., Reg. Sess. (Pa. 2021) (see also S.B. 100, 205th Gen.
Assemb., Reg. Sess. (Pa. 2021) for Senate version); Assemb. B. 7495, 244th Ann. Legis. Sess. (N.Y.);
Assemb.730, 220th Leg., 2022 Sess. (N.J. 2022).
169. CONN. GEN. STAT. § 38a-492h (2018).
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specializations listed in the statute.170 Interestingly, Connecticut treatment
laws for Lyme disease allow extended treatment by certified physicians,
physician assistants, and advanced practice registered nurses,171 but the
state limits insurance coverage to only those who seek care from a
rheumatologist, infectious disease specialist or neurologist. Thus, if a
patient wants to obtain care from a Lyme-literate doctor, who may not fit
into one of the specified medical sub-divisions, the State will not require
an insurance provider to cover that patient’s care.
The Massachusetts law, on the other hand, does not exclude any
category of physician and requires coverage of medication even if it is
considered experimental.172 Coverage of experimental medication is
necessary because insurance companies often label antibiotic treatment for
chronic Lyme disease as experimental.173 Finally, the law requires
coverage based on “patient’s symptoms, diagnostic test results or response
to treatment.”174 Use of the word “or” is important because patients with
chronic Lyme disease do not always test positive due to the low quality of
the CDC-approved blood test, as explained in Part I.175
New Hampshire’s law builds on Massachusetts’s law by expanding
coverage to all tick-borne illnesses and forbidding insurance companies
from charging higher deductibles, co-payments, or coinsurance than other
illnesses. It states:
Each insurer . . . shall provide . . . coverage for long-term antibiotic
therapy for tick-borne illness when determined to be medically
necessary and ordered by a licensed infectious disease physician after
making a thorough evaluation of the patient’s symptoms, diagnostic
test results or response to treatment. Benefits provided under this
section shall not be subject to any greater co-payment, deductible, or
coinsurance than any other similar benefits provided by the
insurer.176

There are two flaws to this law, however. First, the law requires
treatment by an infectious disease doctor, which is an issue because many
Lyme-literate doctors are not infectious disease doctors, as noted above.

170. What Makes a Doctor Lyme Literate?, supra note 87.
171. CONN. GEN. STAT. § 20-14m(b) (2021).
172. MASS. GEN. LAWS ch. 175, § 47HH (2017).
173. For example, Aetna states the following: “Aetna considers additional antibiotic therapy in
post-treatment, persistently fatigued patients (post-Lyme disease syndrome) experimental and
investigational because IV antibiotic therapy has not been shown to be effective for this indication.”
Aetna Clinical Policy, supra note 26.
174. MASS. GEN. LAWS ch. 175, § 47HH (2017).
175. Treseler, supra note 167.
176. N.H. REV. STAT. § 415:18-ee (2021).
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And second, the law limits coverage to antibiotics, which may mean that
non-antibiotic drugs are not covered.
Finally, while Maine has not yet passed an insurance coverage
mandate for Lyme disease, the State does require insurance accountability:
[A]ll carriers shall file with the superintendent for the most recent
calendar year for all covered individuals in the State the total claims
made for the diagnosis and treatment of Lyme disease and other tickborne illnesses. The filing must include information on the number
of claims made for the diagnosis and treatment of Lyme disease and
other tick-borne illnesses, the total dollar amount of those claims, the
number of claim denials and the reasons for those denials, the number
and outcome of internal appeals and the number of external appeals
related to the diagnosis and treatment of Lyme disease and other tickborne illnesses.177

Maine’s statute requires insurance companies to report whether
Lyme disease patients are receiving reimbursement for their treatment,
which provides the State with an accurate picture of the cost of the illness
and the number of individuals seeking treatment. The statute also likely
encourages insurance companies to apply fair standards because the
companies know denials are being tracked.178 Even so, without an
insurance coverage mandate, some patients’ treatment costs may fall
through the cracks in Maine.
State insurance tracking is important, but as Meland points out, “[a]n
inherent shortcoming in statewide initiatives is that they do not fully assist
in solving a national problem. Instead, they are merely pieces of a larger
puzzle.”179 In order to solve this national dilemma, Congress must pass
comprehensive national legislation requiring insurance coverage and
tracking. New Hampshire’s insurance law with minor modifications could
form a strong basis for a federal insurance mandate. In addition, Maine’s
insurance tracking law could provide a key framework for ensuring
compliance.
VI. THE WORLD HEALTH ORGANIZATION RECOGNIZES CHRONIC LYME
DISEASE
A recent human rights report presented to the World Health
Organization (WHO) highlighted human rights violations associated with
Lyme disease in an effort to update the International Classification of

177. ME. REV. STAT. tit. 24-A, § 4302 (2019).
178. Meland, supra note 130, at 137.
179. Id.
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Diseases Codes (ICD codes).180 ICD codes “are used globally to identify
and record diseases, injuries[,] and deaths. In many countries, ICD codes
are tied to insurance plans and reimbursement for medical care.”181 The
current ICD10 codes for Lyme disease are limited and do not characterize
chronic Lyme disease in healthcare databases.182 Thus, insurance
companies who use the codes for reimbursement purposes may not feel
obligated to provide full payment.
The human rights report highlighted ten human rights violations
against Lyme disease patients and six defender human rights violations
against physicians treating Lyme disease patients caused by denial of care
and the targeting of treating physicians.183 It cites government failure to
require healthcare coverage for Lyme disease as an “obstruction to
necessary medical care for those with insufficient economic resources to
pay out-of-pocket.”184
As a result of the human rights report and the WHO’s review of new
scientific studies, in 2018 the WHO acknowledged the complexity of
Lyme disease by publishing new, expanded medical codes specific to
Lyme disease as part of ICD11.185 The number of medical complications
associated with Lyme disease will increase from three in ICD10 to
fourteen in ICD11, five of which acknowledge life-threatening
complications, and thirteen of the fourteen apply to chronic Lyme.186
Notably, ICD11 diagnosis codes do not include the condition “Post-Lyme
Disease Syndrome,” which is the term the CDC, IDSA, and many
insurance companies use to deny treatment for chronic Lyme disease.187
180. JENNA LUCHÉ-THAYER, $LYME: HOW MEDICAL CODES MORTALLY WOUND CORRUPTION
10, 74 (2018) [hereinafter $LYME].
181. Id. at 10.
182. See id. at 82–85.
183. See JENNA LUCHÉ-THAYER, HOLLY AHERN, ROBERT BRANSFIELD, JOSEPH BURRASCANO,
ANNE FIERLAFIJN, THERESA DENHAM, HUIB KRAAIJEVELD, JENNIFER KRAVIS, MUALLA MCMANUS,
CLEMENT MESEKO, JACK LAMBERT, SIN HANG LEE, KENNETH LIEGNER, CHRISTIAN PERRONNE,
KENNETH SANDSTRÖM, URSULA TALIB, TORBEN THOMSEN & JIM WILSON, THE SITUATION OF
HUMAN RIGHTS DEFENDERS OF LYME AND RELAPSING FEVER BORRELIOSIS PATIENTS 13–15 (1st ed.
2018).
184. Id. at 14.
185. See ICD-11 for Mortality and Morbidity Statistics, ICD, https://icd.who.int/browse11/lm/en (follow ICD-11 hyperlink; then search “Lyme”) See also T. BEDIRHAN ÜSTÜN, ROBERT JAKOB,
CAN ÇELIK, PIERRE LEWALLE & NENAND KOSTANJSEK, PRODUCTION OF ICD-11: THE OVERALL
REVISION
PROCESS,
WHOFIC
NETWORK
4
(Mar.
2007)
https://www.who.int/classifications/icd/ICDRevision.pdf [https://perma.cc/3P62-MV5C] (explaining
the WHO’s revision process).
186. Id.; $LYME, supra note 180, at 84–85. After publication of $LYME, the WHO removed the
code for congenital Lyme. See John S. Lambert & Christian Perronne, Time to Recognise Congenital
Lyme: An Open Letter to the WHO, LYME RES. CTR. (June 24, 2020),
https://www.lymeresourcecentre.com/who-letter-20200624 [https://perma.cc/VPH9-H56V].
187. Id. at 86.
AND SCIENTIFIC FRAUD
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The U.S. will soon begin the process of adopting the new ICD11
codes for use in all medical facilities.188 The new ICD11 codes should help
convince Congress to create legislation enforcing insurance coverage for
chronic Lyme disease treatment.
VII. PROPOSAL
A. Outlining Legislation
Congress must pass a bill requiring insurance coverage and the
tracking of insurance claims for chronic Lyme disease treatment based on
clinical diagnoses and ILADS Guidelines. Scientists have collected
overwhelming evidence of persistent infection associated with Lyme
disease, and the WHO acknowledges persistent manifestations of Lyme
disease through its adaptation of ICD11. Failure to implement insurance
mandates for treatment and track insurance claim denials will result in
continued denial of desperately needed medical treatment for patients
across the country by allowing the IDSA and insurance companies to
control the market, restrict access for patients seeking care under the
ILADS Guidelines, and reduce the number of Lyme-literate doctors.
Therefore, the proposed legislative solution has two parts: (1) mandatory
coverage and (2) mandatory claims reporting, as outlined below.
1. Part 1: Mandating Insurance Coverage
Part one of the new federal legislation must mandate insurance
coverage for all insurance types, including private insurance, Medicare,
and Medicaid, for Lyme disease diagnostic testing, treatment, and doctors’
visits even if such treatment is listed as experimental or investigational by
insurance companies. Denial of access to healthcare is a human rights
violation. Without insurance or government provided healthcare coverage,
Lyme disease treatment continues to be unavailable to low-income
patients who are unable to pay for large medical bills out-of-pocket.
Patients along with their physicians should have the ability to choose
between the two treatment guidelines, IDSA or ILADS, based on
individual considerations and the risk of chronic infection.
Studies have shown that Lyme is a regressive illness, meaning that
failure to treat at an early stage could lead to future treatment failure and
chronic illness.189 Therefore, mandatory treatment coverage could result
in fewer complications from the illness, fewer claims for extended
188. Margaret A. Skurka, ICD-11: U.S. Lags in Adoption, ICD10 MONITOR (Nov. 2, 2020),
https://www.icd10monitor.com/icd-11-u-s-lags-in-adoption [https://perma.cc/PS3N-G7MS].
189. See, e.g., Cameron, supra note 31, at 470, 471–72.
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treatment required to cure chronic Lyme disease, and potentially fewer
long-term disability and social security claims. Mandatory treatment
coverage has potential benefits for insurance companies as well. As
Richard Blumenthal testified, “[G]ood medicine and humane treatment of
patients and consumers often can be good business for these HMOs and
insurers…. [O]ften, by treating early or adopting preventative medical
care, in the long run there’s less expense.”190 Mandating coverage would
also remove the need for internal costs related to preauthorization and
oversight because there would no longer be a question of whether or not
treatment should be covered.191 In addition, a 2014 Massachusetts study
revealed that monthly premiums would only increase between a negligible
amount and $0.11 or 0.02% per year if long term antibiotic treatment for
Lyme disease were covered based on the proposed Massachusetts state
bill.192
Congress should implement New Hampshire’s law with four
modifications: (1) remove the requirement for the prescribing doctor to be
an infectious diseases doctor because many experienced Lyme-literate
doctors are not infectious disease doctors, (2) expand the definition of
therapy to include any drug type, not just antibiotics, (3) add coverage of
both experimental and investigational treatment so that drugs used offlabel193 are covered and (4) include doctors’ visits as well. These proposed
changes and safeguards will help to ensure the most coverage for the most
patients.
2. Part 2: Mandating Insurance Claim Tracking
Part two of the new federal legislation must require insurance
companies to track insurance claims similar to Maine’s statutory
scheme.194 According to the Institute of Medicine’s report on chronic
infections, “[h]aving better data will inform planning, development,
implementation, and evaluation of public health policies, programs, and
190. Chronic Lyme Hearing NY, supra note 154, at 79–80 (Statement of Richard Blumenthal,
Atty Gen. Connecticut).
191. See id. at 75. (Blumenthal is referring to Anthem, which eliminated prior authorization
review for IV antibiotics in the wake of Connecticut’s Lyme disease insurance mandate law).
192. MANDATED BENEFIT REVIEW OF H.B. 989: AN ACT RELATIVE TO LYME DISEASE
TREATMENT COVERAGE, CTR. FOR HEALTH INFO. & ANALYSIS 2 (2014); see also S.B. 100, 205th
Gen. Assemb., Reg. Sess. (Pa. 2021).
193. The term “off-label” refers to the use of an FDA approved drug for an unapproved use.
Understanding Unapproved Use of Approved Drugs “Off Label,” U.S. FOOD & DRUG ADMIN. (Feb.
5,
2018),
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatmentoptions/understanding-unapproved-use-approved-drugs-label [https://perma.cc/CT48-2ZN8] (The
FDA provides the following example of off-label drug use on its website: “when a chemotherapy is
approved to treat one type of cancer, but healthcare providers use it to treat a different type of cancer.”).
194. ME. REV. STAT. tit. 24-A, § 4302 (2019).

2022]

It's About Lyme

79

community-based interventions for individuals living with chronic
illness.”195 Current tracking for Lyme disease is limited to cases reported
to the CDC, general records from insurance collection databases, and
patient surveys, each of which have their own limitations.
First, the CDC receives approximately 35,000 reports of Lyme
disease each year, but estimates the true number of cases may be closer to
476,000 due to undercounting.196 Undercounting is especially prevalent in
southern and western states where the CDC implements stricter criteria for
confirmed cases.197
Second, the IBM Watson Health MarketScan Commercial Claims
and Encounters Databases, used as part of the CDC’s case estimate, only
compile general healthcare claims from approximately 25 million
privately insured U.S. residents.198 But given the U.S.’s population of
approximately 330 million199 and the study’s exclusion of people aged 65
and older, as well as individuals without private insurance,200 the data can
only be viewed as an incomplete estimation and appears to lack
information on claim denials and appeals.
Finally, LymeDisease.org publishes important studies on access to
treatment and the burden of care for Lyme disease patients, but data is
limited to patients who enroll in MyLymeData voluntarily, and thus only
provides a snapshot of the larger national issue.201
National legislation, which matches Maine’s insurance reporting
requirements, is the only viable solution to harness an accurate count of
Lyme disease diagnoses. Mandating data on the number of Lyme disease
claims, claim denials, and appeals from insurance companies, Medicare,
and Medicaid, will hold insurance companies accountable and provide a
more accurate count of people who are diagnosed, treated, and denied
coverage. Further, the proposed legislation will fill information gaps

195. Inst. of Med., Living Well with Chronic Illness: A Call for Public Health Action, 180 MIL.
MED. 485, 486 (2015) [hereinafter Living Well with Chronic Illness].
196. How Many People Get Lyme Disease?, supra note 21.
197. Lorraine Johnson, How Much Does the CDC Undercount Lyme Cases? It Depends on
Where You Live, LYMEDISEASE.ORG (Feb. 2, 2021), https://www.lymedisease.org/cdc-lyme-diseasecasesundercount/?fbclid=IwAR14kZJXotZgvwrNFT3LTuH_jvLpvTngBtSRihB01zrJwHei0IeXu9a07bw
[https://perma.cc/W6PV-2ZK2]; see also 2ND REPORT TO CONGRESS, supra note 25, at 91.
198. Kiersten J. Kugeler, Amy M. Schwartz, Mark J. Delorey, Paul S. Mead & Alison F.
Hinckley, Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010–2018, 27
EMERGING INFECTIOUS DISEASES 616, 616 (2021) [hereinafter Estimating the Frequency].
199. U.S. and World Population Clock, U.S. CENSUS BUREAU (Jan. 23, 2021),
https://www.census.gov/popclock/ [https://perma.cc/LSC3-QFYR].
200. Estimating the Frequency, supra note 198, at 616.
201. See MYLYMEDATA REGISTRY, supra note 61, at ii, 24.
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identified by the CDC. 202 Without data on claim denials, the government
will be unable to pursue insurance companies who fail to comply with part
one of this legislation.
B. National Problems Require National Solutions
While some may argue that states are more equipped to handle
insurance related needs than the federal government, federal legislation on
insurance mandates for specific illnesses do exist, and have increased over
the years.203 For example, federal law requires insurance companies to
cover reconstructive surgery after mastectomies, hospital stays post birth
for a minimum amount of time, and mental health needs equivalent to
physical health needs, in addition to the expanded requirements under the
Affordable Care Act.204 Further, since Lyme disease patients live in all
fifty states,205 the current state legislation found in only eight states is
woefully inadequate to help the hundreds of thousands of people who are
diagnosed each year throughout the country. Federal legislation will afford
all Lyme disease patients equal access to insurance coverage, regardless
of their geographic location or insurance type, and will smooth out
inconsistencies currently seen in state legislation.206
A federal mandate like this is not unprecedented. The Women’s
Health and Cancer Rights Act, Section 1185b of ERISA, requires coverage
for reconstructive surgery of both breasts following a mastectomy for
symmetrical appearance.207 The Legislative hearing on the Women’s
Health and Cancer Rights Act of 1997 provides insight into why Congress
believed federal, rather than state law, was necessary to provide such
coverage.208 Senator D’Amato testified that an identical bill was passed in
the New York State Legislature, but because ERISA preempts state laws
for healthcare covered by employer paid plans, a full 40% of the insured
population did not receive benefits from the state law.209 Similarly, ERISA
law likely preempts state insurance laws on Lyme disease for some
patients. In addition, because most cases of Lyme disease occur in specific
regions of the U.S., patients in states with lower incident rates are less
202. Estimating the Frequency, supra note 198, at 618 (“Further studies of coding patterns and
improved access to and use of electronic health records could fill . . . data gaps, enabling more robust
and precise estimates in the future.”).
203. See NICOLE HUBERFELD, ELIZABETH WEEKS, KEVIN OUTTERSON, THE LAW OF AMERICAN
HEALTH CARE 223 (2nd ed. 2018).
204. Id.
205. Searing, supra note 22.
206. See generally Hoffman, supra note 159, at 240.
207. 29 U.S.C. § 1185b.
208. See Women’s Health and Cancer Rights Act of 1997: Hearing on S. 249 Before the
Subcomm. on Health Care, 105th Cong. 6 (1997) (statement of Sen. Alfonse D’Amato).
209. Id.
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likely to successfully campaign for legislative insurance coverage because
Lyme disease may not be a priority for their states’ legislature.
Additionally, under the Mental Health Parity Act, Congress ensures
people with mental health (MH) and substance use disorders (SUD)
receive comparable medical care to people with other forms of illness.210
The Act mandates that insurance companies, who provide MH and SUD
coverage, provide as much coverage for MH and SUD as they do for any
other medical or surgical procedure.211 Cost was one of the major concerns
among insurers and employers when the original 1996 law was expanded
in 2008, but new research offered evidence that the expanded parity bill
would only raise premiums by 0.9%.212 This new research convinced
coverage providers that the federal mandate would not be cost
prohibitive.213 Insurance providers are likely to have similar cost concerns
over the coverage of Lyme disease treatment, but monthly premiums may
only increase by 0.02% per year if long term antibiotic treatment for Lyme
disease were covered, per a Massachusetts study.214
The proposed Lyme insurance law is like the Mental Health Parity
Law in many ways. First, the Parity Law requires almost all insurance
plans to follow the Federal Parity Law including small and large
employers, individual, Children’s Health Insurance Program (CHIP),
government employer, and some Medicaid plans.215 The vast coverage
pool is important to achieve maximum benefits for a large portion of the
population, a similar concern for Lyme disease patients. Second, the
federal Parity Law requires full coverage of prescription drugs equal to
those provided for medical or surgical reasons.216 Full prescription drug
coverage is essential for Lyme patients because they are often denied
coverage for antibiotics after a certain amount of time, regardless of the
success of treatment. For comparison, similar denial of medication for
patients with other chronic infectious diseases, like HIV, would be
unheard of.217 The similarities between the Parity Law and the proposed
Lyme disease insurance coverage law show why an insurance mandate for
Lyme is well within Congress’s power to mandate.

210. See 29 U.S.C. § 1185a(a)(1)(A), (B).
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213. Id. at 414–15.
214. MANDATED BENEFIT REVIEW OF H.B. 989: AN ACT RELATIVE TO LYME DISEASE
TREATMENT COVERAGE, CTR. FOR HEALTH INFO. & ANALYSIS 2 (2014).
215. HEALTH INSURANCE FOR ADDICTION & MENTAL HEALTH CARE, LEGAL ACTION CTR.10
(2016).
216. Id. at 20.
217. Davidsson, supra note 93, at 41.
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Congress is willing and able to create federal insurance mandates for
specific illnesses when it sees the need. Lyme disease insurance laws at
the state level are ineffective for two reasons. First, due to preemption by
ERISA, many patients will fall through the cracks, as Senators from New
York found after a full 40% of their state’s population did not receive
benefits from the reconstructive surgery post mastectomy state law.218
Second, a lack of legislative interest in states with perceived low-incidence
rates means that Lyme patients in those states will be discriminated against
by insurance companies based solely on their current geographic location.
Federal legislation will remove restrictions based on geographic locations
and will likely result in nominal changes in costs of coverage as seen in
the Massachusetts study.219
Without specific federal legislation addressing the discrimination of
patients with Lyme disease by insurance companies, insurance companies
will continue to deny medical treatment to chronic Lyme disease patients.
Federal legislation is therefore necessary to ensure that Lyme disease
patients receive insurance coverage, whether it be through private
insurance or government subsidized plans.
VIII. CONCLUSION
As the medical industry continues to debate the scientific aspects of
Lyme disease, thousands of patients, particularly chronically ill patients,
fight their illness with little to no help from health insurance providers.
Without federal legislation to ensure access to reimbursement, most
patients will continue to face financial challenges, and some will be forced
to discontinue treatment, which can have fatal consequences, as illustrated
by Ms. Logan’s story. Therefore, Congress has a duty to Lyme disease
patients to pass comprehensive Lyme disease insurance coverage
legislation. By creating insurance mandates for all treatment and doctors’
visits, even if they are considered experimental, insurance companies will
no longer be able to discriminate against Lyme disease patients. In
addition, by mandating that insurance companies report claims and denials
to Congress, the U.S. government will finally have an accurate
understanding of the number of people suffering from the illness, the true
cost of Lyme disease, and an enforcement mechanism to ensure
compliance.
The Institute of Medicine proclaims: “living with chronic illnesses
has not been given the attention it deserves by health care funders, health
218. Women’s Health and Cancer Rights Act of 1997: Hearing on S. 249 Before the Subcomm.
on Health Care, 105th Cong. 6 (1997) (statement of Sen. Alfonse D’Amato).
219. See MANDATED BENEFIT REVIEW OF H.B. 989: AN ACT RELATIVE TO LYME DISEASE
TREATMENT COVERAGE, CTR. FOR HEALTH INFO. & ANALYSIS 2 (2014).

2022]

It's About Lyme

83

systems, policy makers, and public health programs and agencies.”220 Now
is the time for the federal government to act.

220. Living Well with Chronic Illness, supra note 195, at 487.

